The company is an innovative enterprise group integrating pharmaceutical R&D, production, sales and medical services. Since its establishment in 2003, it has always adhered to the corporate tenet of “flexible intelligence, focus on health”. After more than ten years of entrepreneurial development, it was listed on the Shanghai Stock Exchange in May 2015. The company is mainly engaged in R&D, production and sales of chemical prescription drugs. The company's leading products cover the three major fields of parenteral nutritional drugs, anti-infective drugs, and digestive medicines. The company has successively won honors such as “China's Innovative Pharmaceutical Enterprises” and “China's Top 100 Comprehensive Pharmaceutical Research and Development Strength List”, and Lingkang Pharmaceutical's “An Omeprazole Sodium Hemihydrate and Preparation Method” patent won the China Patent Excellence Award.